Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may forecast survival in intensive care patients

NCT ID NCT07682766

Recruiting now Knowledge-focused Sponsor: University of Turin, Italy Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at whether measuring certain immune and inflammatory markers in the blood can help predict how critically ill patients will fare. Researchers are following 200 adults in intensive care who have infections, have had major surgery, or have weakened immune systems. They will track markers like procalcitonin and interleukin-6 over time and see if they relate to survival, organ damage, and complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which critically ill patients are at highest risk of death or complications, enabling earlier and more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. The findings may not apply to all hospital settings or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOCOMPROMISED PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOCOMPROMISED PATIENTS SEPTIC SHOCK

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AOU Città della Salute e della Scienza

    RECRUITING

    Torino, 10126, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.